Erik Faber MD PhD
@fabermdphd.bsky.social
Onc fellow @mskcancercenter.bsky.social | #medchem 💊 PhD | aspiring #GIOnc doc | 🐶 dad | ex-HS teacher 🧑🏫 | @oslerresidency.bsky.social @umnmedchem.bsky.social @dartmouthartsci.bsky.social alum | 🏳️🌈 he/him | #mdphd #doubledocs
2/2
pubmed.ncbi.nlm.nih.gov/40827837/
Disrupting CDK2/cyclin PPI like our work did ;) but via orthosteric inhibitors causing global conformational changes. However unclear why this works for cyclin A2 complexes but not cyclin E ones, and surprising given nM affinity b/w CDKs and cyclins #medchem
pubmed.ncbi.nlm.nih.gov/40827837/
Disrupting CDK2/cyclin PPI like our work did ;) but via orthosteric inhibitors causing global conformational changes. However unclear why this works for cyclin A2 complexes but not cyclin E ones, and surprising given nM affinity b/w CDKs and cyclins #medchem
Fulcrum Occupancy-Leverage Perturbation Strategy Enables Rapid Discovery of Potent CDK2-Cyclin A2 Interaction Inhibitors - PubMed
Traditional strategies for developing small-molecule inhibitors of protein-protein interactions (PPIs) are time-consuming and often yield low success rates due to the flat and dynamic interfaces of PP...
pubmed.ncbi.nlm.nih.gov
September 27, 2025 at 3:09 PM
2/2
pubmed.ncbi.nlm.nih.gov/40827837/
Disrupting CDK2/cyclin PPI like our work did ;) but via orthosteric inhibitors causing global conformational changes. However unclear why this works for cyclin A2 complexes but not cyclin E ones, and surprising given nM affinity b/w CDKs and cyclins #medchem
pubmed.ncbi.nlm.nih.gov/40827837/
Disrupting CDK2/cyclin PPI like our work did ;) but via orthosteric inhibitors causing global conformational changes. However unclear why this works for cyclin A2 complexes but not cyclin E ones, and surprising given nM affinity b/w CDKs and cyclins #medchem